Future epidemic impact of atrial fibrillation and a new interventional strategy for stroke prophylaxis

Future Cardiology

Volumn 7, Issue 2, 2011, Pages 219-226

  Schmid, Michael ^a   Khattab, Ahmed A ^a   Gloekler, Steffen ^a   Meier, Bernhard ^a  

^a PSI   (Switzerland)

Author keywords

anticoagulation; atrial fibrillation; left atrial appendage; stroke; transcatheter LAA occlusion

Indexed keywords

WARFARIN;

ANTICOAGULATION; BLEEDING; CARDIOVASCULAR RISK; CATHETER OCCLUSION; CEREBROVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG EFFICACY; HEART ASSIST DEVICE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROPHYLAXIS; RADIOFREQUENCY ABLATION; REVIEW; SEPTAL OCCLUDER; STROKE; THORACOTOMY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; HUMANS; INCIDENCE; PRACTICE GUIDELINES AS TOPIC; STROKE; WORLD HEALTH;

EID: 79953753378     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.122     Document Type: Review

References (29)

1. Heeringa J, van der Kuip DA, Hofman A et al.: Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart J. 27(8), 949-953 (2006).
2. Schnabel RB, Sullivan LM, Levy D et al.: Development of a risk score for atrial fibrillation (Framingham Heart Study), a community-based cohort study. Lancet 373(9665), 739-745 (2009).
3. Go AS, Hylek EM, Phillips KA et al.: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285 (18), 2370-2375 (2001).
4. Vaziri SM, Larson MG, Benjamin EJ, Levy D: Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 89(2), 724-730 (1994).
5. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98(10), 946-952 (1998).
6. Kolb C, Nurnberger S, Ndrepepa G, Zrenner B, Schomig A, Schmitt C: Modes of initiation of paroxysmal atrial fibrillation from analysis of spontaneously occurring episodes using a 12-lead Holter monitoring system. Am. J. Cardiol. 88(8), 853-857 (2001).
7. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285(22), 2864-2870 (2001).
8. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M: Stroke incidence, case fatality, and mortality in the WHO MONICA project: World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. Stroke 26(3), 361-367 (1995).
9. Harrison MJ, Marshall J: Atrial fibrillation, TIAs and completed strokes. Stroke 15(3), 441-442 (1984).
10. Mant J, Hobbs FD, Fletcher K et al.: Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA), a randomised controlled trial: Lancet 370(9586), 493-503 (2007).
11. van Walraven C, Hart RG, Connolly S et al.: Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 40(4), 1410-1416 (2009).
12. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B: Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1(8631), 175-179 (1989).
13. Rockson SG, Albers GW: Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J. Am. Coll. Cardiol. 43(6), 929-935 (2004).
14. Ezekowitz MD, Levine JA: Preventing stroke in patients with atrial fibrillation. JAMA 281(19), 1830-1835 (1999).
15. Landefeld CS, Beyth RJ: Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am. J. Med. 95(3), 315-328 (1993).
16. Lip GY, Lim HS: Atrial fibrillation and stroke prevention. Lancet Neurol. 6(11), 981-993 (2007).
17. Calkins H, Reynolds MR, Spector P et al.: Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ. Arrhythm. Electrophysiol. 2(4), 349-361 (2009).
18. Miyazaki S, Kuwahara T, Kobori A et al.: Long-term clinical outcome of extensive pulmonary vein isolation-based catheter ablation therapy in patients with paroxysmal and persistent atrial fibrillation. Heart (2010) (Epub ahead of print).
19. Blackshear JL, Odell JA: Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann. Thorac. Surg. 61(2), 755-759 (1996).
20. Garcia-Fernandez MA, Perez-David E, Quiles J et al.: Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. J. Am. Coll. Cardiol. 42(7), 1253-1258 (2003).
21. Johnson WD, Ganjoo AK, Stone CD, Srivyas RC, Howard M: The left atrial appendage: our most lethal human attachment! Surgical implications. Eur. J. Cardiothorac. Surg. 17(6), 718-722 (2000).
22. Blackshear JL, Johnson WD, Odell JA et al.: Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. J. Am. Coll. Cardiol. 42(7), 1249-1252 (2003).
23. Sievert H, Lesh MD, Trepels T, Omran H et al.: Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 105(16), 1887-1889 (2002).
24. Meier B, Palacios I, Windecker S et al.: Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc. Interv. 60(3), 417-422 (2003).
25. Block PC, Burstein S, Casale PN et al.: Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) study. JACC Cardiovasc. Interv. 2(7), 594-600 (2009).
26. Holmes DR, Reddy VY, Turi ZG et al.: Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet 374(9689), 534-542 (2009).
27. Sick PB, Schuler G, Hauptmann KE et al.: Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J. Am. Coll. Cardiol. 49(13), 1490-1495 (2007).
28. Ostermayer SH, Reisman M, Kramer PH et al.: Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J. Am. Coll. Cardiol. 46(1), 9-14 (2005).
29. Gloekler S, Schmid M, Khattab AA, Windecker S, Meier B: Percutaneous transcatheter occlusion of the left atrial appendage in patients with atrial fibrillation with a new device: early efficacy and safety results. Eur. Heart J. 31(Suppl.), 921 (2010).